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Background: Common cell based strategies for the treatment of osseous defects require the isolation and
expansion of autologous cells. Since this makes such approaches time-consuming and expensive, we developed a
novel expedited technology creating gene activated muscle grafts. We have previously shown that large segmental
bone defects in rats can be regenerated by implantation of muscle tissue fragments activated by BMP-2 gene
transfer.
Results: In the present study, we compared the bone healing capacities of such gene activated muscle grafts with
bone isografts, mimicking autologous bone grafting, the clinical gold standard for treatment of bone defects in
patients. Two of 14 male, syngeneic Fischer 344 rats used for this experiment served as donors for muscle and
bone. Muscle tissue was harvested from both hind limbs and incubated with an adenoviral vector carrying the
cDNA encoding BMP-2. Bone was harvested from the iliac crest and long bone epiphyses. Bone defects (5 mm)
were created in the right femora of 12 rats and were filled with either BMP-2 activated muscle tissue or bone grafts.
After eight weeks, femora were evaluated by radiographs, micro-computed tomography (μCT), and biomechanical
testing. In the group receiving BMP-2 activated muscle grafts as well as in the bone-grafting group, 100% of the
bone defects were healed, as documented by radiographs and μCT-imaging. Bone volume was similar in both
groups and biomechanical stability of the two groups was statistically indistinguishable.
Conclusions: This study demonstrates that treatment of large bone defects by implantation of BMP-2 gene activated
muscle tissue leads to similar bone volume and stability as bone isografts, mimicking autologous bone grafting.
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Tissue engineeringBackground
Large bone defects are hard to treat and cause pain, dis-
ability and high cost. Autologous bone grafting is the
clinical gold standard for the regeneration of large de-
fects in patients. However, the limited amount of bone
tissue available for autografting and donor site morbidity
represent significant drawbacks of this method [1-3].
Bone morphogenetic proteins are clinically used for the* Correspondence: Oliver.Betz@med.uni-muenchen.de
1Department of Orthopedic Surgery, Laboratory for Biomechanics and
Experimental Orthopedics, University Hospital Grosshadern, Ludwig-
Maximilians-University Munich, Marchioninistrasse 23, 81377 Munich,
Germany
Full list of author information is available at the end of the article
© 2013 Betz et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortreatment of long-bone fractures and for enhanced spinal
fusion [4-8] but their delivery needs improvement due to
their short biological half-lives [9,10]. Gene transfer is an
improved way of delivering such growth factors as it is
possible to achieve high concentrations locally for an ex-
tended period of time [11-13]. A suitable vector for the
purpose of inducing bone growth in a lesion is adenovirus
as it is a non-integrating vector with high transduction ef-
ficiency. Additionally, in vivo expression stops after about
six weeks which may just provide enough stimulus for
bone repair avoiding the risk of excessive ectopic over-
growth of bone. In previous studies, we evaluated the ef-
fects of direct in vivo gene delivery to bone defects in a rat. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to further improve bone repair by gene therapy, we believe
that it is necessary to supply not only an osteogenic gene,
but also stem cells and a scaffold. Most ex vivo gene ther-
apy approaches utilize these three ingredients. The com-
bination of growth factor over-expressing bone marrow
derived cells [17,18], fat derived cells [19] and skin cells
[20] together with a matrix has successfully induced bone
formation in vivo. It has also been demonstrated that
muscle derived stem cells have the potential to differenti-
ate towards the osteogenic lineage and effectively regener-
ate bone defects in pre-clinical animal models [21,22].
Although ex vivo gene therapy has been very successful in
pre-clinical bone repair models, the method is time-
consuming and expensive as it requires the isolation and
expansion of autologous progenitor cells. For this reason,
we developed an expedited ex vivo gene therapy approach
which is characterized by the direct transfer of BMP-2
cDNA to muscle tissue fragments without extracting cells
from this tissue. In a recent study, we demonstrated that
such expedited gene activated muscle grafts successfully
induce repair of large segmental bone defects in rats [23].
The harvest of muscle tissue is a frequently used proced-
ure in reconstructive surgery and only minor donor site
morbidity was reported after harvesting the vastus lateralis
muscle or the gracilis muscle [24,25]. Muscle tissue could
therefore be a practicable source for the augmentation of
bone defects after BMP-2 gene activation. Since autolo-
gous bone grafting is the clinical gold standard for the re-
pair of osseous defects in patients we compared our novel
expedited ex vivo gene therapy approach to this gold
standard evaluating repair of critical-sized femoral bone
defects in rats.
Results
Six femora of the group treated with Ad.BMP-2 gene acti-
vated muscle grafts and six of the bone grafting group
were evaluated by radiographs, micro-computed tomog-
raphy (μCT) and biomechanical torsional testing. Intra-
and postoperatively, there were no complications and we
did not see wound infections or delayed wound healing.
The rats were able to bear their full weight on the oper-
ated limbs from the day of surgery until they were eutha-
nized. Gene activated muscle grafts were well tolerated
and produced no obvious adverse effects during the eight
weeks of the experiment. All animals showed a normal
eating pattern and no weight loss was recorded.
Measurement of BMP-2 up-regulation by ELISA
On day six after transduction BMP-2 up-regulation was
confirmed by ELISA. BMP-2 transduced muscle discs
produced 5260 ± 3158 pg/ml BMP-2. BMP-2 concentra-
tion in supernatants of controls was 68 ± 52 pg/ml
(unmodified muscle).Radiographic evaluation
100% (six out of six) of the animals treated with Ad.
BMP-2 gene activated muscle grafts showed united
bones at eight weeks after treatment (Figure 1A-F), and
100% (six out of six) of the femora treated with bone
grafts appeared united radiographically (Figure 1G-L).
Micro-computed tomography (μCT)
Images: All six femora receiving Ad.BMP-2 gene acti-
vated muscle grafts displayed bridging of the 5 mm de-
fects at eight weeks (Figure 2A-F and M-R). In the bone
grafting group, μCT-imaging, in contrast to the conven-
tional radiographic evaluation (Figure 1), reveals incom-
plete bridging of some defects (Figure 2G-L and S-X).
Bone volume
The bone volume of femora treated with BMP-2 gene
activated muscle tissue (33.44 ± 12.26 mm3) was statisti-
cally indistinguishable from that of femora treated with
bone grafts (39.66 ± 4.63 mm3) (p = 0.12) (Figure 3).
Biomechanical testing
The mechanical properties of the femora treated with
BMP-2 activated muscle grafts were evaluated by torsional
testing and compared to properties of femora treated with
bone grafts. Femora treated with BMP-2 activated muscle
grafts showed a torque to failure (238.47 ± 114.54 Nmm)
and a torsional stiffness (23.50 ± 10.79 Nmm/rad) that
were in the range of the femora treated with bone grafts
(231.59 ± 108.36 Nmm) respectively (37.70 ± 25.03 Nmm/
rad) with no statistically significant difference (p = 0.87
and p = 0.42, respectively) (Figure 4-A and 4-B).
Discussion
The rare disease fibrodysplasia ossificans progressiva
(FOP) taught us that constitutive activation of a BMP
type I receptor causes bone growth in muscle tissue
[26]. The fact that BMP signaling leads to bone forma-
tion in muscle was exploited in our experiment and en-
abled us to develop a novel abbreviated ex vivo gene
transfer approach to bone healing. In this study, bone
formation was reliably induced after implantation of
BMP-2 activated muscle tissue and all defects of this
group were bridged at eight weeks. Bone volumes mea-
sured in former defect areas were similar after treatment
with gene activated muscle compared to autologous
bone grafting. Biomechanical stability was statistically in-
distinguishable. We repeatedly report successful bone
defect repair using the gene activated muscle graft tech-
nology. In addition to our previous study where we eval-
uated healing in the same animal model [23], we were
now able to demonstrate that BMP-2 activated muscle
repairs large bone defects as effectively as bone grafting.
The reason for this success might be that we not only
Figure 1 Radiographic images. Radiographic images of femoral segmental bone defects 8 weeks after surgery. Femora treated with BMP-2
gene activated muscle grafts (A - F) and autologous bone grafts (G – L) displayed complete bridging of the defect.
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vided a natural degradable scaffold and stem cells by
implanting muscle tissue. To our knowledge, this is the
first comparison between a cell-based bone repair tech-
nology and autologous bone grafting in a pre-clinical
large segmental bone defect model. Many researchers
may eschew this comparison but we believe that, right
from the beginning in a small animal model, a novel ap-
proach must demonstrate at least equal effectiveness as
compared to the clinical gold standard. The fact that we
see similar effectiveness encourages us to further de-
velop and improve the technology in order to exceed the
efficacy of autologous bone grafting. Compared to bone
autograft muscle tissue can be harvested in larger quan-
tities causing only low donor site morbidity [24,25] and,
once gene transfer to muscle grafts has been optimized,
it might be a more potent graft material showing higher
osteoinductivity leading to faster and more robust bone
defect healing.
Soft tissue defects require the use of muscle flaps fre-
quently. It was shown, that the harvest of the vastus
lateralis or the gracilis muscle only leads to minimal donor
site morbidity and even the complete absence of these
muscles rarely caused lower extremity weakness [24,25].
The harvest of either of those muscles in humans should
enable us to fill even large, critical size bone defects.
Upscaling to a large animal model using autograft muscle
tissue is the focus of our current research activity.
Conventional ex vivo approaches for bone regeneration
have been successful in pre-clinical experiments but could
not enter widespread clinical use due to complexity and
high cost. The most expensive steps are cell isolation andexpansion of autologous progenitor cells performed over
several weeks under GMP conditions. Instead, if produc-
tion of a cell-based implant took only 1–2 days chances
for translation into a clinical setting rose. Another expe-
dited gene transfer strategy is the direct percutaneous in-
jection of viral vector into a bone lesion. This approach
was investigated in our former studies and led to bone for-
mation in the same femoral defect rat model. However,
bone healing was not as robust and reliable as seen with
the here presented muscle graft method. Also, the direct
in vivo gene transfer led to ectopic bone formation due to
leakage of the viral vector.Conclusion
We conclude that the here presented gene activated
muscle graft technology can be considered as an expedited
approach combining safety features of ex vivo gene ther-
apy with the simplicity of a direct in vivo approach, espe-
cially when applied during a single surgical step. This
novel abbreviated gene-enhanced bone repair method
should have the potential to be performed during a single
surgery as genetically manipulation by adenovirus can be
completed within 1 to 2 hours. To demonstrate this, in
one of our next studies we will take muscle tissue from
a rat, genetically modify the tissue fragments intra-
operatively and re-implant the gene activated tissue into a
bone defect of the same rat. Expedited, cost-effective bone
regeneration strategies are of great interest as economic
burdens impede translation of most common cell-based
therapies. In this rat study we were able to show that
BMP-2 over-expressing autologous muscle grafts repair
Figure 2 Micro-CT images. Micro-CT images of femoral segmental bone defects treated with BMP-2 gene activated muscle grafts (A – F) and
autologous bone grafts (G – L) and longitudinal, medial sections of micro-CT images of femoral segmental bone defects treated with BMP-2
gene activated muscle grafts (M – R) and autologous bone grafts (S – X) 8 weeks after surgery. All images of the femora treated with BMP-2
gene activated muscle grafts (A – F and M – R) displayed complete bridging and regeneration of cortical bone and cancellous bone formation
in the medullary cavity. The micro-CT-images of the autologous bone graft group (G – L and S – X) revealed incomplete bridging of several
defects (U, V and W).
Betz et al. BMC Biotechnology 2013, 13:65 Page 4 of 8




14 male syngeneic Fischer 344 rats (weight 300–350 g)
were used for this study. Bone and muscle tissue were
harvested from two euthanized donor rats. A 5 mm, crit-
ical sized mid-femoral defect was created in the right hind
limb of each of 12 rats and stabilized by an internal fixator.
The rats were divided in two groups. Bone defectsreceived either muscle grafts activated by an adenoviral
vector carrying the human BMP-2 cDNA (Ad.BMP-2)
(n = 6) or bone grafts (n = 6). At eight weeks after surgery
healing of the femora was evaluated by radiographs,
micro-computed tomography (μCT) and biomechanical
testing.
Vector production
Serotype 5, E1, E3 deleted, first generation adenoviral
vector was constructed by amplification of the hBMP-2
coding region by PCR-amplified cloning it into the
Figure 3 Bone volume determined by micro-CT. Micro-CT
evaluation of the bone volume of defects treated with autologous
bone grafts and BMP-2 activated muscle grafts. Values given
represent means ± SD; (autologous bone grafts, n = 6; BMP-2
activated muscle grafts, n = 6). No statistically significant difference in
bone volume of femora receiving autologous bone grafts versus
BMP-2 activated muscle grafts could be determined (p = 0.12).
Figure 4 Mechanical properties of bones. (A) Torque to failure and (B)
activated muscle grafts 8 weeks after surgery. Values given represent mean
n = 6). No statistically significant difference in torque to failure (p = 0.87) or
activated muscle grafts could be determined (p = 0.42).
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open reading frame in the resulting vector pO6A5-CMV
-hBMP-2 was confirmed by sequence analysis. The CMV-
BMP-2 portion of pO6A5-CMV-hBMP-2 was then trans-
ferred via recombination in a BAC vector containing the
genome of a replication deficient Ad5-based vector de-
leted in E1/E3 genes. Following release of the recombinant
viral DNA by restriction digest with PacI HEK-293 cells
were transfected with the adenoviral DNA and infectious
particles were generated. The amplified viral particles were
chromatographically purified using ViraBind™ Adenovirus
Purification Kit (Cell Biolabs Inc.). Infectious titers were
determined via immunohistochemical detection of the
adenoviral hexon protein in infected HEK 293 cells.
Tissue harvest
Bone and muscle tissue were harvested from two donor
animals. Bone was taken from the iliac crest and epiphyses
of long bones and muscle was harvested from the upper
thighs. Both tissues were washed with phosphate buffered
saline and transferred into a Petri dish. Muscle tissue was
cut under sterile conditions into slices of approximately
1 mm thickness. Discs were then punched out using a
4 mm dermal biopsy punch to create fragments of a stan-
dardized size and placed in 24-well plates. No cell isolation
was performed. Muscle tissue was then transduced with
an adenoviral BMP-2 vector (see “Activation of Muscle
Tissue Grafts”). Harvested bone was cut into 1 to 2 mm
fragments and placed in 24-well plates. DMEM media
(BiochromeAG, Berlin, Germany) was added to the bone
fragments and grafts were placed in an incubator for 24 –
48 hours prior to implantation. Fischer 344 rats are genet-
ically identical animals that allow transplantation of tissuestiffness of femora treated with autologous bone grafts and BMP-2
s ± SD; (autologous bone grafts, n = 6; BMP-2 activated muscle grafts,
stiffness of femora receiving autologous bone grafts versus BMP-2
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versus-graft immune response known from allograft trans-
plantation [27-29]. For practical and logistical reasons we
used this well established syngeneic rodent autotransplant
model, harvested bone and muscle tissue from two eutha-
nized donor rats, implanted the tissue into femoral bone
lesions of 12 syngeneic rats and thereby mimicked auto-
graft transplantation.
Activation of muscle tissue grafts
Right after harvest muscle tissue fragments were infected
with 1 × 108 plaque forming units (pfu) of Ad.BMP-2. Viral
particles were appropriately diluted in phosphate buffered
saline (PBS) and a volume of 10 μL was applied directly to
the surface of the tissue grafts using a micro pipette. Then
the tissue fragments were placed in an incubator (37°C, 5%
CO2) for 60 minutes. In order to avoid dilution of the vec-
tor concentration no cell media was added to the tissue.
The virus solution and the humidified air in the incubator
kept the tissue fragments moist during incubation. Then
DMEM media (BiochromeAG, Berlin, Germany) was
added and the muscle tissues were placed back in the incu-
bator for 24 – 48 hours prior to implantation.
Measurement of BMP-2 up-regulation by ELISA
Four muscle discs in 700 μl of DMEM media per well
were held in culture using a 24-well plate. Media was
changed every third day. The supernatants of untreated
muscle and BMP-2-transduced muscle were harvested
on day six and BMP-2 up-regulation was measured by
ELISA. Measurements were performed in quadruplicate
(n = 4).
Surgical procedure
All operative procedures were approved by the animal wel-
fare committee of Bavaria, Germany (“Regierung von
Oberbayern”). A modified version of an established,
critical-size, femoral defect rat model [14,16,30], was used
in this study. The animals were placed under general
anesthesia by the administration of isoflurane using a
small-animal vaporizer at initially 4% isoflurane in 2 L O2/
min and then 2% isoflurane in 2 L O2/min to maintain.
Following anesthesia, the animals received intramuscular
injections of 0.025 mg/kg buprenorphine (analgetic) into
the left thigh. After aseptical preparation for surgery, an
approximately 40 mm long skin incision was created over
the right femur and underlying soft tissue was retracted to
reveal the bone. Two transcortical holes were drilled in a
latero-medial plane in the proximal femur using a 0.9 mm
drill bit (Gebr. Brasseler GmbH, Lemgo, Germany) and a
second pair was placed in the distal femur, leaving enough
space for creating the defect. Four pins (1.1 mm, threaded
Kirschner-wires) (MicroAire, Charlottesville, VA, USA)
were then placed into the femur and cut off to a length ofapproximately 20 mm. Two fixator plates were placed on
top of each other and secured to the ends of the pins using
mini-screws. A 5 mm osteotomy was then created in the
center of the bone between the two inner pins using a ster-
ile, round dental burr (Gebr. Brasseler GmbH, Lemgo,
Germany) attached to a dental hand piece (Modell 174025,
Eichenmayer KG, Tuttlingen, Germany). After completion
of the osteotomy, the site was copiously irrigated with
saline.Implantation of bone and muscle tissue grafts
Excessive vector was washed off by placing the muscle tis-
sue grafts in a 50 ml Falcon tube filled with PBS. PBS was
replaced four times and the tube was shaken gently. The
muscle grafts were then implanted within the segmental
bone defects of six animals. A staple of five tissue fragments
was “press fitted” into the defect without securing the im-
plants to the periosteum. Another six animals received
bone grafts that were washed four times with PBS prior to
implantation. After implantation of the grafts the muscle fa-
sciae were closed using 3–0 chromic cat gut suture. The
two fixator plates were lowered down consecutively to a
distance of about 5 mm above the surrounding muscle sur-
face and secured to the pins. The pins were cut to be flush
with the plates and the skin incision was closed over the
plates using 4–0 silk suture. Right after surgery, the animals
received an intramuscular injection of 0.025 mg/kg bup-
renorphine for additional analgesia. During the first
48 hours after surgery, each animal received intramuscular
injections of 0.05 mg/kg buprenorphine every 12 hours.
Animals were killed 8 weeks after surgery. The femora were
harvested, fresh frozen and stored at −20°C prior to evalu-
ation by X-ray, micro-computed tomography and biomech-
anical testing.Radiographic evaluation and Micro-computed
tomography (μCT)
Femora were scanned using a desktop micro-tomographic
imaging system (μCT80, Scanco Medical AG, Brüttisellen,
Switzerland) equipped with a 10 mm focal spot mic-
rofocus X-ray tube. The scout view X-ray image was saved
for the radiographic evaluation. The entire defect region
was scanned using a 20 μm isotropic voxel size, at 70 keV
energy, 400 ms integration time and requiring approxi-
mately 420 μCT slices per specimen. In the defect region
only 3 mm bone volume was analyzed for each specimen
to ensure that no old cortical bone was included in the
analyses. Images were thresholded using an adaptive-
iterative algorithm [31,32] and morphometric variables
were computed from the binarized images using direct,
3D techniques that do not rely on any prior assumptions
about the underlying structure [33].
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Following imaging, 6 femora treated with BMP-2 activated
muscle grafts and 6 femora treated with bone grafts were
tested to failure in torsion on a biaxial testing machine
(Instron 8874; High Wycombe, UK). Both ends of each
specimen were embedded using PMMA (Technovit 3040;
Heraeus Kulzer, Germany) to provide an appropriate and
reproducible gripping interface with the testing module.
In order to avoid lateral forces and bending moments
caused by clamping, a special manufactured device was
used to place the specimen during the embedding process.
This enabled us to embed the bone ends in the center of
the PMMA disc and aligned the longitudinal axis of the
bones with the torsion axis. Specimens were tested to fail-
ure rotation at a constant deformation rate of 5 rad/min
angular deformation and applied load data were acquired
at 10 Hz. Due to the potential shortening of the femora
during torsion and the resulting tensile force along the
longitudinal axis of the bones, a constant axial load of 5 N
was applied during the test. The torsional stiffness was cal-
culated from each torque rotation diagram. The torque to
failure was defined as the first maximum in the torque ro-
tation diagram.
Statistical methods
Statistical significance of the biomechanical data and
the bone volume data was determined by using the
Mann–Whitney U-test. (p < 0.05 was considered statis-
tically significant).
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